What is the difference in clinical significance and management between a positive Clostridioides difficile toxin assay and a positive C. difficile antigen (glutamate‑dehydrogenase) test?

C. difficile Toxin Positive vs Antigen (GDH) Positive: Clinical Significance and Management

Patients who are toxin-positive should be treated for active C. difficile infection, while those who are GDH-positive but toxin-negative (requiring NAAT confirmation) may represent colonization or lower-risk disease and should be managed based on clinical context rather than reflexively treated. 1

Understanding the Test Results

Toxin-Positive Patients (GDH+/Toxin+)

These patients have active toxin production and represent true C. difficile infection requiring treatment. Key clinical characteristics include:

• Higher mortality risk: 30-day mortality significantly elevated compared to toxin-negative patients 1
• More severe disease: 34% present with severe/severe-complicated forms vs 19% in toxin-negative patients 2
• Higher recurrence rates: 25.5% vs 7.2% in toxin-negative/PCR-positive patients 2
• More pronounced clinical features: Greater leukocytosis, elevated creatinine, hypoalbuminemia, and longer duration of diarrhea 1

GDH-Positive/Toxin-Negative Patients

This represents a diagnostic gray zone requiring additional testing with NAAT for confirmation. The clinical significance depends on NAAT results:

If NAAT-positive (GDH+/Toxin-/NAAT+):

• May represent colonization or early/resolving infection rather than active disease
• CDI-related complications occur in 0% vs 7.6% in toxin-positive patients 1
• CDI-related mortality essentially zero (0% vs 8.4% in toxin-positive patients) 1
• However, 91.5% may still have clinically diagnosed CDI requiring individualized assessment 1
• Important caveat: GDH positivity independently predicts in-hospital mortality (adjusted OR 2.19) and prolonged hospitalization even when toxin-negative 3

If NAAT-negative (GDH+/Toxin-/NAAT-):

• Likely represents non-toxigenic C. difficile or false-positive GDH
• Does not require CDI treatment
• May warrant infection control precautions as potential excretors

Recommended Diagnostic Algorithm

The IDSA/SHEA 2018 guidelines recommend a multistep algorithm rather than toxin testing alone 1:

1. Screen with GDH (high sensitivity, detects presence of organism)
2. If GDH-positive: Perform toxin A/B EIA
3. If toxin-positive: Treat as active CDI
4. If toxin-negative: Arbitrate with NAAT to distinguish colonization from infection

This 2- or 3-stage approach increases positive predictive value compared to single-test strategies 1.

Treatment Decision Framework

Treat immediately if:

• Toxin EIA positive (regardless of other test results)
• Clinical symptoms strongly suggest CDI (≥3 loose stools in ≤24 hours with antibiotic exposure) 1

Consider treatment with clinical correlation if:

• GDH+/Toxin-/NAAT+ with compatible clinical syndrome
• Symptoms worsening despite negative initial testing
• High clinical suspicion in epidemic settings 1

Do NOT treat if:

• GDH+/Toxin-/NAAT- without compelling clinical features
• Asymptomatic patients (testing should not be performed) 1
• Formed stool specimens

Critical Pitfalls to Avoid

1. Over-reliance on NAAT alone: Using NAAT as a standalone test leads to overdiagnosis, as it detects colonization (10-15% of hospitalized patients) as well as active infection 1

2. Repeat testing within 7 days: Diagnostic yield is only ~2% and risks false-positives; do not retest unless clinical presentation changes significantly 1

3. Testing asymptomatic patients: Never perform C. difficile testing on formed stools or asymptomatic individuals outside epidemiological studies 1

4. Ignoring GDH-positive/toxin-negative results: These patients still have worse outcomes than test-negative patients and require clinical vigilance even if not treated for CDI 3

5. Treating based solely on PCR positivity: Approximately 45% of patients with discordant results (toxigenic culture or NAAT positive but toxin-negative) did not even have documented diarrhea 1

Key Clinical Distinctions

Toxin-positive patients are older, have more severe laboratory abnormalities, and face substantially higher risks of complications and death. The presence of free toxin in stool correlates with active disease requiring treatment, while detection of organism alone (GDH or NAAT positive, toxin-negative) often represents colonization that poses infection control risk but may not require antimicrobial therapy 1.

The sensitivity of toxin EIA varies significantly by assay (69-82%), which is why the multistep algorithm improves diagnostic accuracy while avoiding overtreatment of colonized patients 1.